

NMDA Agonists and Antagonists as Probes of Glutamate Pharmacotherapies in Neuropsychiatric Disorders

Harvard Review of Psychiatry

7, 125-143

DOI: [10.3109/hrp.7.3.125](https://doi.org/10.3109/hrp.7.3.125)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists. <i>Neuropsychopharmacology</i> , 1999, 21, S143-S157.	2.8	59
2	The schizophrenia ketamine challenge study debate. <i>Biological Psychiatry</i> , 1999, 46, 1081-1091.	0.7	63
3	Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. <i>Biological Psychiatry</i> , 1999, 46, 1060-1080.	0.7	27
4	Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine. <i>Archives of General Psychiatry</i> , 2000, 57, 270.	13.8	414
5	Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. <i>Trends in Neurosciences</i> , 2001, 24, 330-334.	4.2	143
6	Genetic animal models: focus on schizophrenia. <i>Trends in Neurosciences</i> , 2001, 24, 527-533.	4.2	197
7	Increased expression of neuronal Src and tyrosine phosphorylation of NMDA receptors in rat brain after systemic treatment with MK-801. <i>Neuropharmacology</i> , 2001, 40, 469-481.	2.0	8
8	Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. <i>Neuropharmacology</i> , 2001, 40, 1003-1009.	2.0	36
9	Neurobiology of Generalized Anxiety Disorder. <i>Psychiatric Clinics of North America</i> , 2001, 24, 75-97.	0.7	65
10	Glutamateâ€”Hypothalamic-Pituitary-Adrenal Axis Interactions: Implications for Mood and Anxiety Disorders. <i>CNS Spectrums</i> , 2001, 6, 555-564.	0.7	39
11	Effects of olfactory bulbectomy on NMDA receptor density in the rat brain: [³ H] MK-801 binding assay. <i>Brain Research</i> , 2001, 900, 214-218.	1.1	26
12	The effect of competitive and non-competitive NMDA receptor antagonists, ACPCand MK-801 on NPY and CRF-like immunoreactivity in the rat brain amygdala. <i>Neuropeptides</i> , 2001, 35, 219-226.	0.9	6
13	Differential and Region-Specific Activation of Mitogen-Activated Protein Kinases Following Chronic Administration of Phencyclidine in Rat Brain. <i>Neuropsychopharmacology</i> , 2001, 24, 267-277.	2.8	32
14	Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men: Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel Antagonists. <i>Neuropsychopharmacology</i> , 2001, 25, 936-947.	2.8	51
15	N-Methyl-d-Aspartic Acid Receptor Expression in the Dorsolateral Prefrontal Cortex of Elderly Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2001, 158, 1400-1410.	4.0	174
16	Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 11047-11054.	3.3	153
17	The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia. <i>American Journal of Psychiatry</i> , 2001, 158, 1367-1377.	4.0	833
19	A Pilot Study of Memantine Effects on Protracted Withdrawal (Syndrome of Anhedonia) in Heroin Addicts. <i>Addictive Disorders and Their Treatment</i> , 2002, 1, 143-146.	0.5	20

#	ARTICLE	IF	CITATIONS
20	Genetics of Childhood Disorders: XLIV. Autism, Part 3: Psychopharmacology of Autism. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2002, 41, 1380-1383.	0.3	26
21	In vivo evaluation of [11C]-3-[2-[(3-methoxyphenylamino)carbonyl]ethenyl]-4,6-dichloroindole-2-carboxylic acid ([11C]3MPICA) as a PET radiotracer for the glycine site of the NMDA ion channel. <i>Nuclear Medicine and Biology</i> , 2002, 29, 791-794.	0.3	13
22	Adaptation of monoaminergic responses to phencyclidine in nucleus accumbens and prefrontal cortex following repeated treatment with fluoxetine or imipramine. <i>Brain Research</i> , 2002, 958, 20-27.	1.1	18
23	NMDA receptor pathways as drug targets. <i>Nature Neuroscience</i> , 2002, 5, 1039-1042.	7.1	443
24	Glutamate Receptor Genes. <i>Molecular Neurobiology</i> , 2002, 25, 191-212.	1.9	43
25	Subunit Selective Decrease of AMPA and Metabotropic Glutamate Receptor mRNA Expression in Rat Brain by Systemic Administration of the NMDA Receptor Blocker MK-801. <i>Journal of Molecular Neuroscience</i> , 2003, 21, 29-34.	1.1	4
26	Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 292-308.	1.8	145
27	NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. <i>Psychopharmacology</i> , 2003, 169, 215-233.	1.5	477
28	Neurobiology of glutamatergic abnormalities in schizophrenia. <i>Clinical Neuroscience Research</i> , 2003, 3, 67-76.	0.8	12
29	Chronically administered guanosine is anticonvulsant, amnesic and anxiolytic in mice. <i>Brain Research</i> , 2003, 977, 97-102.	1.1	93
30	Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. <i>European Journal of Pharmacology</i> , 2003, 461, 93-98.	1.7	18
31	NMDA Receptor Activity and the Transmission of Sensory Input into Motor Output in Introverts and Extraverts. <i>Quarterly Journal of Experimental Psychology Section B: Comparative and Physiological Psychology</i> , 2003, 56, 207-221.	2.8	9
32	Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal lesioned rats: reversal by glycine and a glycine transporter inhibitor. <i>Biological Psychiatry</i> , 2003, 54, 1162-1170.	0.7	108
33	The neurobiology and control of anxious states. <i>Progress in Neurobiology</i> , 2003, 70, 83-244.	2.8	815
34	Corticosterone alters N-methyl-d-aspartate receptor subunit mRNA expression before puberty. <i>Molecular Brain Research</i> , 2003, 115, 55-62.	2.5	83
35	Imaging the PCP site of the NMDA ion channel. <i>Nuclear Medicine and Biology</i> , 2003, 30, 869-878.	0.3	50
36	Management of the Negative Symptoms of Schizophrenia. <i>CNS Drugs</i> , 2003, 17, 793-823.	2.7	111
37	Decreased Serum Levels of D-Serine in Patients With Schizophrenia. <i>Archives of General Psychiatry</i> , 2003, 60, 572.	13.8	461

#	ARTICLE	IF	CITATIONS
38	A Pilot Study of Cycloserine in Subjects With Autistic Disorder. <i>American Journal of Psychiatry</i> , 2004, 161, 2115-2117.	4.0	180
39	Neuregulin 1 and schizophrenia. <i>Annals of Medicine</i> , 2004, 36, 62-71.	1.5	119
40	Identification of Genes Regulated by Memantine and MK-801 in Adult Rat Brain by cDNA Microarray Analysis. <i>Neuropsychopharmacology</i> , 2004, 29, 1070-1079.	2.8	36
41	Reduced isolation-induced aggressiveness in mice following NAALADase inhibition. <i>Psychopharmacology</i> , 2004, 171, 375-381.	1.5	35
42	Mitochondria, Synaptic Plasticity, And Schizophrenia. <i>International Review of Neurobiology</i> , 2004, 59, 273-296.	0.9	160
43	Glutamate and anxiety. <i>European Neuropsychopharmacology</i> , 2004, 14, 175-183.	0.3	183
44	The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. <i>Neuropharmacology</i> , 2004, 47, 1135-1145.	2.0	29
45	In vivo evaluation of [¹¹ C]N-(2-chloro-5-thiomethylphenyl)-N-ε-(3-methoxy-phenyl)-N-ε-methylguanidine ([¹¹ C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor. <i>Nuclear Medicine and Biology</i> , 2004, 31, 939-948.	0.3	27
46	Continuous exposure to nitric oxide enhances diazepam binding inhibitor mRNA expression in mouse cerebral cortical neurons. <i>Molecular Brain Research</i> , 2004, 124, 29-39.	2.5	9
47	The Role of Glutamate in Anxiety and Related Disorders. <i>CNS Spectrums</i> , 2005, 10, 820-830.	0.7	196
48	Neuregulin 1 gene and variations in perceptual aberration of schizotypal personality in adolescents. <i>Psychological Medicine</i> , 2005, 35, 1589-1598.	2.7	59
49	NAAG peptidase inhibitors and their potential for diagnosis and therapy. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 1015-1026.	21.5	207
50	Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. <i>European Journal of Pharmacology</i> , 2005, 519, 114-117.	1.7	128
51	mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. <i>Journal of Neuroscience Research</i> , 2005, 79, 868-878.	1.3	73
52	Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. <i>Psychopharmacology</i> , 2005, 179, 303-309.	1.5	255
53	Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. <i>Psychopharmacology</i> , 2005, 179, 154-163.	1.5	160
54	Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. <i>Psychopharmacology</i> , 2005, 179, 136-143.	1.5	33
55	Limbic system: temporal lobe. , 2005, , 178-200.		0

#	ARTICLE	IF	CITATIONS
56	What is Known About Autism. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 71-92.	3.3	155
57	On the trail of a cognitive enhancer for the treatment of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 219-232.	2.5	74
58	Identification of Multiple Serine Racemase (SRR) mRNA Isoforms and Genetic Analyses of SRR and DAO in Schizophrenia and d-Serine Levels. <i>Biological Psychiatry</i> , 2005, 57, 1493-1503.	0.7	138
59	Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study. <i>Schizophrenia Research</i> , 2005, 79, 157-173.	1.1	204
60	Slow-Binding Human Serine Racemase Inhibitors from High-Throughput Screening of Combinatorial Libraries. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2388-2397.	2.9	34
61	Mechanism of action of memantine. <i>Current Opinion in Pharmacology</i> , 2006, 6, 61-67.	1.7	390
62	Analysis of correlation between serum d-serine levels and functional promoter polymorphisms of GRIN2A and GRIN2B genes. <i>Neuroscience Letters</i> , 2006, 394, 101-104.	1.0	10
63	Glycine Transporter Inhibitors as Therapeutic Agents for Schizophrenia. <i>Recent Patents on CNS Drug Discovery</i> , 2006, 1, 43-53.	0.9	32
65	Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults.. <i>Experimental and Clinical Psychopharmacology</i> , 2006, 14, 439-449.	1.3	45
66	LY404187: A Novel Positive Allosteric Modulator of AMPA Receptors. <i>CNS Neuroscience & Therapeutics</i> , 2002, 8, 255-282.	4.0	83
67	ACEA 1021: Flip or Flop?. <i>CNS Neuroscience & Therapeutics</i> , 2004, 10, 337-348.	4.0	2
68	In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. <i>Psychopharmacology</i> , 2006, 185, 240-247.	1.5	31
69	Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 84, 259-265.	1.3	23
70	Major affective disorders and schizophrenia: a common molecular signature?. <i>Human Mutation</i> , 2006, 27, 833-853.	1.1	40
72	Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism. <i>Neuropsychopharmacology</i> , 2006, 31, 1793-1800.	2.8	48
73	Genetic Inactivation of the NMDA Receptor NR2A Subunit has Anxiolytic- and Antidepressant-Like Effects in Mice. <i>Neuropsychopharmacology</i> , 2006, 31, 2405-2414.	2.8	200
74	Atypical Antipsychotics and a Src Kinase Inhibitor (PP1) Prevent Cortical Injury Produced by the Psychomimetic, Noncompetitive NMDA Receptor Antagonist MK-801. <i>Neuropsychopharmacology</i> , 2006, 31, 1420-1430.	2.8	33
75	Effects of the NMDA Antagonist Ketamine on Task-Switching Performance: Evidence for Specific Impairments of Executive Control. <i>Neuropsychopharmacology</i> , 2006, 31, 1675-1681.	2.8	58

#	ARTICLE	IF	CITATIONS
76	Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors. <i>Neuropsychopharmacology</i> , 2007, 32, 514-521.	2.8	123
77	Minocycline Attenuates Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Administration of the NMDA Receptor Antagonist Dizocilpine. <i>Neuropsychopharmacology</i> , 2007, 32, 2004-2010.	2.8	95
78	Memantine Treatment of Complex Regional Pain Syndrome. <i>Clinical Journal of Pain</i> , 2007, 23, 237-243.	0.8	66
79	Lamotrigine as Add-On Therapy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 582-589.	0.7	112
80	Psychosis: Atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?. <i>Epilepsy and Behavior</i> , 2007, 10, 515-520.	0.9	17
81	SSR180711, a Novel Selective $\alpha 7$ Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia. <i>Neuropsychopharmacology</i> , 2007, 32, 17-34.	2.8	239
82	Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy. <i>Biological Psychiatry</i> , 2007, 62, 833-834.	0.7	29
83	Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. <i>Molecular Psychiatry</i> , 2007, 12, 74-86.	4.1	386
84	Hippocampal abnormalities and memory deficits: New evidence of a strong pathophysiological link in schizophrenia. <i>Brain Research Reviews</i> , 2007, 54, 92-112.	9.1	155
85	Psychiatric safety of ketamine in psychopharmacology research. <i>Psychopharmacology</i> , 2007, 192, 253-260.	1.5	104
86	Systemic Neurochemical Alterations in Schizophrenic Brain: Glutamate Metabolism in Focus. <i>Neurochemical Research</i> , 2007, 32, 1434-1444.	1.6	23
87	Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 258, 16-27.	1.8	90
88	The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. <i>Current Psychiatry Reports</i> , 2007, 9, 467-474.	2.1	199
89	A Double-blind Placebo Controlled Trial of Piracetam Added to Risperidone in Patients with Autistic Disorder. <i>Child Psychiatry and Human Development</i> , 2008, 39, 237-245.	1.1	51
90	Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. <i>Neuroscience and Biobehavioral Reviews</i> , 2008, 32, 1014-1023.	2.9	294
91	Chronic Administration of Ketamine Elicits Antidepressant-Like Effects in Rats without Affecting Hippocampal Brain-Derived Neurotrophic Factor Protein Levels. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 502-506.	1.2	101
92	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 426-437.	21.5	761
93	Phencyclidine-Induced Cognitive Deficits in Mice Are Improved by Subsequent Subchronic Administration of the Novel Selective $\alpha 7$ Nicotinic Receptor Agonist SSR180711. <i>Biological Psychiatry</i> , 2008, 63, 92-97.	0.7	104

#	ARTICLE	IF	CITATIONS
94	A pharmacological MRI assessment of dizocilpine (MK-801) in the 3-nitropropionic acid-lesioned rat. <i>Neuroscience Letters</i> , 2008, 444, 42-47.	1.0	14
95	Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 140-144.	2.5	377
96	Developing New Drugs for Schizophrenia: From Animals to the Clinic. , 2008, , 199-261.		18
97	d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. <i>Behavioural Brain Research</i> , 2008, 186, 78-83.	1.2	158
98	Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and d-serine. <i>European Neuropsychopharmacology</i> , 2008, 18, 414-421.	0.3	67
99	Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: Role of serotonin 5-HT1A receptors. <i>European Neuropsychopharmacology</i> , 2008, 18, 448-454.	0.3	58
100	Switching schizophrenia patients from typical neuroleptics to olanzapine: Effects on BOLD response during attention and working memory. <i>European Neuropsychopharmacology</i> , 2008, 18, 589-599.	0.3	50
101	Association study between genetic variants at the VAMP2 and VAMP3 loci and bipolar affective disorder. <i>Psychiatric Genetics</i> , 2008, 18, 199-203.	0.6	10
102	Ketamine induces rapid onset of antidepressant action: neurophysiological biomarkers as predictors of effect. <i>Biomarkers in Medicine</i> , 2009, 3, 5-8.	0.6	3
103	Mutant mice with reduced NMDA-NR1 glycine affinity or lack of d-amino acid oxidase function exhibit altered anxiety-like behaviors. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 91, 610-620.	1.3	64
104	Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. <i>Drug Discovery Today</i> , 2009, 14, 690-697.	3.2	60
105	Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors. <i>Brain Research</i> , 2009, 1279, 189-196.	1.1	63
106	Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress. <i>Brain Research Bulletin</i> , 2009, 79, 418-421.	1.4	54
107	Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801. <i>Behavioural Brain Research</i> , 2009, 204, 410-415.	1.2	88
108	Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 450-455.	2.5	214
109	Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: A possible role of α 1-adrenoceptors. <i>European Neuropsychopharmacology</i> , 2009, 19, 861-867.	0.3	33
110	Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. <i>Revista Brasileira De Psiquiatria</i> , 2009, 31, 247-252.	0.9	28
111	Effect of chronic administration of ketamine on the mitochondrial respiratory chain activity caused by chronic mild stress. <i>Acta Neuropsychiatrica</i> , 2010, 22, 292-299.	1.0	12

#	ARTICLE	IF	CITATIONS
112	Limbic system: Temporal lobe. , 0 , 176-196.		0
113	Gamma and Delta Neural Oscillations and Association with Clinical Symptoms under Subanesthetic Ketamine. <i>Neuropsychopharmacology</i> , 2010, 35, 632-640.	2.8	238
114	Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies. <i>American Journal of Psychiatry</i> , 2010, 167, 261-280.	4.0	1,068
115	De Novo Truncating Mutation in Kinesin 17 Associated with Schizophrenia. <i>Biological Psychiatry</i> , 2010, 68, 649-656.	0.7	43
116	Switching schizophrenia patients from typical neuroleptics to aripiprazole: Effects on working memory dependent functional activation. <i>Schizophrenia Research</i> , 2010, 118, 189-200.	1.1	51
117	Effects of moderate exercise on cigarette smoke exposure-induced hippocampal oxidative stress values and neurological behaviors in mice. <i>Neuroscience Letters</i> , 2010, 475, 16-19.	1.0	35
118	Behavioral alterations and pro-oxidant effect of a single ketamine administration to mice. <i>Brain Research Bulletin</i> , 2010, 83, 9-15.	1.4	75
119	Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. <i>Neuroscience</i> , 2010, 168, 209-218.	1.1	48
120	Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain. <i>Experimental Neurology</i> , 2010, 224, 207-218.	2.0	45
121	Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. <i>European Neuropsychopharmacology</i> , 2010, 20, 25-36.	0.3	54
122	Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention. <i>Biological Psychology</i> , 2011, 88, 83-93.	1.1	33
123	Individual differences in maternal response to immune challenge predict offspring behavior: Contribution of environmental factors. <i>Behavioural Brain Research</i> , 2011, 220, 55-64.	1.2	51
124	Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test. <i>Behavioural Brain Research</i> , 2011, 225, 328-333.	1.2	61
125	Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. <i>Neuroscience Letters</i> , 2011, 500, 167-171.	1.0	46
126	The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 198-202.	2.5	72
127	In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. <i>Nuclear Medicine and Biology</i> , 2011, 38, 517-527.	0.3	12
128	Effect of the Selective NMDA NR2B Antagonist, Ifenprodil, on Acute Tolerance to Ethanol-induced Motor Impairment in Adolescent and Adult Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 1149-1159.	1.4	12
129	d-Serine: The right or wrong isoform?. <i>Brain Research</i> , 2011, 1401, 104-117.	1.1	32

#	ARTICLE	IF	CITATIONS
130	Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice. <i>Journal of Neural Transmission</i> , 2011, 118, 857-864.	1.4	16
131	Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. <i>Psychopharmacology</i> , 2011, 217, 13-24.	1.5	56
132	Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. <i>Journal of Psychopharmacology</i> , 2011, 25, 1207-1225.	2.0	22
133	Group II Metabotropic Glutamate Receptor Agonist Ameliorates MK801-Induced Dysfunction of NMDA Receptors via the Akt/GSK-3 β Pathway in Adult Rat Prefrontal Cortex. <i>Neuropsychopharmacology</i> , 2011, 36, 1260-1274.	2.8	58
134	Prevention of the Phencyclidine-Induced Impairment in Novel Object Recognition in Female Rats by Co-Administration of Lurasidone or Tansospirone, a 5-HT1A Partial Agonist. <i>Neuropsychopharmacology</i> , 2012, 37, 2175-2183.	2.8	41
135	Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. <i>Pharmacogenomics Journal</i> , 2012, 12, 246-254.	0.9	44
136	Evidence for involvement of nitric oxide and GABAB receptors in MK-801- stimulated release of glutamate in rat prefrontal cortex. <i>Neuropharmacology</i> , 2012, 63, 575-581.	2.0	38
137	Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. <i>Psychopharmacology</i> , 2012, 220, 627-637.	1.5	127
138	The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. <i>Psychopharmacology</i> , 2012, 221, 205-215.	1.5	79
139	Effects of AS2586114, a soluble epoxide hydrolase inhibitor, on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 110, 98-103.	1.3	14
140	Anxiety in Parkinson's Disease. , 2013, , 17-29.		6
141	In vivo glutamate measured with magnetic resonance spectroscopy: behavioral correlates in aging. <i>Neurobiology of Aging</i> , 2013, 34, 1265-1276.	1.5	69
142	NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: A meta-analysis of case-control studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1587-1596.	2.9	31
143	Neuropeptide S inhibits release of 5-HT and glycine in mouse amygdala and frontal/prefrontal cortex through activation of the neuropeptide S receptor. <i>Neurochemistry International</i> , 2013, 62, 360-366.	1.9	6
144	Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 367-377.	1.8	177
145	Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: Role of indirect 5-HT1A partial agonism. <i>Behavioural Brain Research</i> , 2013, 247, 158-164.	1.2	26
146	D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats. <i>Behavioural Brain Research</i> , 2013, 238, 36-43.	1.2	38
147	Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator <scp>CDPPB</scp> on phencyclidine-induced cognitive deficits in mice. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 483-488.	1.0	44

#	ARTICLE	IF	CITATIONS
148	Early stage development of the glycine re-uptake inhibitor <sc>SCH</sc> 900435: central nervous system effects compared with placebo in healthy men. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1455-1467.	1.1	8
149	Deregulation of glutamate dehydrogenase in human neurologic disorders. <i>Journal of Neuroscience Research</i> , 2013, 91, 1007-1017.	1.3	29
150	Neonatal Disruption of Serine Racemase Causes Schizophrenia-Like Behavioral Abnormalities in Adulthood: Clinical Rescue by D-Serine. <i>PLoS ONE</i> , 2013, 8, e62438.	1.1	27
151	The mGlu2/3 Receptor Agonists LY354740 and LY379268 Differentially Regulate Restraint-Stress-Induced Expression of c-Fos in Rat Cerebral Cortex. <i>Neuroscience Journal</i> , 2013, 2013, 1-8.	2.3	20
152	Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. <i>Frontiers in Pharmacology</i> , 2014, 5, 10.	1.6	59
153	Effects of single and combined gabapentin use in elevated plus maze and forced swimming tests. <i>Acta Neuropsychiatrica</i> , 2014, 26, 307-314.	1.0	11
154	Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates. <i>Translational Psychiatry</i> , 2014, 4, e481-e481.	2.4	42
155	Targeting of NMDA receptors in new treatments for schizophrenia. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1049-1063.	1.5	101
156	Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 124, 245-249.	1.3	38
157	Involvement of the Striatal Medium Spiny Neurons of the Direct Pathway in the Motor Stimulant Effects of Phencyclidine. <i>International Journal of Neuropsychopharmacology</i> , 2015, 19, pyv134.	1.0	5
158	Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. <i>Acta Neuropsychiatrica</i> , 2015, 27, 159-167.	1.0	43
159	Measure of anxiety-related behaviors and hippocampal BDNF levels associated to the amnesic effect induced by MK-801 evaluated in the modified elevated plus-maze in rats. <i>Physiology and Behavior</i> , 2015, 147, 359-363.	1.0	20
160	Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia. <i>Biological Psychiatry</i> , 2015, 78, 754-762.	0.7	137
161	R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. <i>Translational Psychiatry</i> , 2015, 5, e632-e632.	2.4	448
162	Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats. <i>Behavioural Brain Research</i> , 2015, 278, 186-192.	1.2	16
163	Psychiatric Morbidity in Ketamine Users Attending Counselling and Youth Outreach Services. <i>Substance Abuse</i> , 2015, 36, 67-74.	1.1	19
164	Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation. <i>Scientific Reports</i> , 2016, 6, 37261.	1.6	33
165	Electrophysiological alterations in a complex rat model of schizophrenia. <i>Behavioural Brain Research</i> , 2016, 307, 65-72.	1.2	17

#	ARTICLE	IF	CITATIONS
166	Serum Magnesium Status in Patients Subjects with Depression in the City of Yazd in Iran 2013â€“2014. <i>Biological Trace Element Research</i> , 2016, 171, 275-282.	1.9	12
167	The Calpain Inhibitor A-705253 Attenuates Alcohol-Seeking and Relapse with Low Side-Effect Profile. <i>Neuropsychopharmacology</i> , 2016, 41, 979-988.	2.8	10
168	Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism. <i>Behavioural Brain Research</i> , 2016, 301, 132-141.	1.2	11
169	Effects of \hat{I}^2 -Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice. <i>Neuropsychopharmacology</i> , 2016, 41, 704-715.	2.8	59
170	Stimulation of the metabotropic glutamate (mGlu) 2 receptor attenuates the MK-801-induced increase in the immobility time in the forced swimming test in rats. <i>Pharmacological Reports</i> , 2016, 68, 80-84.	1.5	9
171	MK-801-Treated Oligodendrocytes as a Cellular Model to Study Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 269-277.	0.8	17
172	5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. <i>Neuropsychopharmacology</i> , 2017, 42, 2163-2177.	2.8	42
173	Clozapine blockade of MK-801-induced learning/memory impairment in the mEPM: Role of 5-HT1A receptors and hippocampal BDNF levels. <i>Physiology and Behavior</i> , 2017, 179, 346-352.	1.0	10
174	Ketamineâ€™s antidepressant effect is mediated by energy metabolism and antioxidant defense system. <i>Scientific Reports</i> , 2017, 7, 15788.	1.6	54
175	An overview on d-amino acids. <i>Amino Acids</i> , 2017, 49, 1521-1533.	1.2	201
176	Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyrmidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1416.	1.8	11
177	Limbic System: Temporal Lobe. , 0, , 164-196.		0
178	Fasting and Fast Food Diet Play an Opposite Role in Mice Brain Aging. <i>Molecular Neurobiology</i> , 2018, 55, 6881-6893.	1.9	23
179	Ketamine: A Promising Rapid-Acting Antidepressant. , 2018, , 223-239.		3
180	Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. <i>International Review of Psychiatry</i> , 2018, 30, 291-316.	1.4	115
181	Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. <i>American Journal of Psychiatry</i> , 2018, 175, 1205-1215.	4.0	338
182	AlphaziumÂ: premiers pas pour un nouveau nutraceutique Ã visÃ©e bien-Ãtre et Ã©quilibre comportemental. <i>Revue Veterinaire Clinique</i> , 2018, 53, 31-38.	0.1	0
183	Biomarker Opportunities to Enrich Clinical Trial Populations for Drug Development in Schizophrenia and Depression. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 103-113.	0.7	0

#	ARTICLE	IF	CITATIONS
184	Structural Evaluation and Electrophysiological Effects of Some Kynurenic Acid Analogs. <i>Molecules</i> , 2019, 24, 3502.	1.7	10
185	Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines. <i>Advances in Pharmacological Sciences</i> , 2019, 2019, 1-20.	3.7	31
186	Nitroergic signaling modulation by ascorbic acid treatment is responsible for anxiolysis in mouse model of anxiety. <i>Behavioural Brain Research</i> , 2019, 364, 85-98.	1.2	10
187	The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. , 2019, , 401-413.		0
188	Ketamine's Effects on the Glutamatergic and GABAergic Systems: A Proteomics and Metabolomics Study in Mice. <i>Molecular Neuropsychiatry</i> , 2019, 5, 42-51.	3.0	15
189	Amantadine exerts anxiolytic like effect in mice: Evidences for the involvement of nitroergic and GABAergic signaling pathways. <i>Behavioural Brain Research</i> , 2020, 380, 112432.	1.2	7
190	Possible Benefits of Considering Glutamate with Melatonin or Orexin or Oxytocin as a Combination Approach in the Treatment of Anxiety. <i>Current Pharmacology Reports</i> , 2020, 6, 1-7.	1.5	8
191	Prefrontal inhibition of neuronal $K_{v}7$ channels enhances prepulse inhibition of acoustic startle reflex and resistance to hypofrontality. <i>British Journal of Pharmacology</i> , 2020, 177, 4720-4733.	2.7	5
192	Disordered directional brain network interactions during learning dynamics in schizophrenia revealed by multivariate autoregressive models. <i>Human Brain Mapping</i> , 2020, 41, 3594-3607.	1.9	16
193	Research progress on the role of type I vesicular glutamate transporter (VGLUT1) in nervous system diseases. <i>Cell and Bioscience</i> , 2020, 10, 26.	2.1	37
194	Clinical overview of NMDA-R antagonists and clinical practice. <i>Advances in Pharmacology</i> , 2020, 89, 103-129.	1.2	9
195	Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects. <i>Psychopharmacology</i> , 2020, 237, 1577-1593.	1.5	11
196	Glutamatergic Contribution to Probabilistic Reasoning and Jumping to Conclusions in Schizophrenia: A Double-Blind, Randomized Experimental Trial. <i>Biological Psychiatry</i> , 2020, 88, 687-697.	0.7	12
197	The effect of 5-HT4 serotonin receptors in the CA3 hippocampal region on D-AP5-induced anxiolytic-like effects: Isobolographic analyses. <i>Behavioural Brain Research</i> , 2021, 397, 112933.	1.2	2
198	Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy. <i>Current Neuropharmacology</i> , 2021, 19, 747-765.	1.4	14
199	Early glutathione intervention educed positive correlation between VGLUT1 expression and spatial memory in the N ^o -nitro-L-arginine methyl rat model of IUGR. <i>IBRO Neuroscience Reports</i> , 2021, 10, 136-141.	0.7	1
200	Effects of NMDA Receptor Antagonists: Implications for the Pathophysiology of Schizophrenia. <i>Archives of General Psychiatry</i> , 2002, 59, 663-664.	13.8	109
201	Developmental Consequences of Prenatal Exposure to Maternal Immune Activation. , 2011, , 263-285.		1

#	ARTICLE	IF	CITATIONS
202	Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Medicinal Chemistry Journal, 2010, 4, 10-19.	0.9	39
203	Effects of D-Amino Acid Oxidase Inhibitor on the Extracellular D-Alanine Levels and the Efficacy of D-Alanine on Dizocilpine-Induced Prepulse Inhibition Deficits in Mice. The Open Clinical Chemistry Journal, 2009, 2, 16-21.	0.7	26
204	Neurotransmission. Medical Psychiatry, 2007, , 81-100.	0.2	2
205	Effects of the Antioxidant Sulforaphane on Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Phencyclidine Administration. Clinical Psychopharmacology and Neuroscience, 2012, 10, 94-98.	0.9	42
206	Glutamatergic Neurotransmission Abnormalities and Schizophrenia. , 2011, , 287-304.		0
207	The Glutamatergic System as Potential Clinical Biomarkers for Blood and Cerebrospinal Fluid Monitoring. Neuromethods, 2018, , 507-521.	0.2	0
208	Plant glutamate receptors mediate a bet-hedging strategy between regeneration and defense. Developmental Cell, 2022, 57, 451-465.e6.	3.1	30
209	Recent advances in dopamine D ₂ receptor ligands in the treatment of neuropsychiatric disorders. Medicinal Research Reviews, 2023, 43, 55-211.	5.0	8
210	Neuropharmacological Modulation of N-methyl-D-aspartate, Noradrenaline and Endocannabinoid Receptors in Fear Extinction Learning: Synaptic Transmission and Plasticity. International Journal of Molecular Sciences, 2023, 24, 5926.	1.8	37